title: Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis.
abstract: OBJECTIVE
  To report a case of anti-glomerular basement membrane disease (anti-GBM disease) during alemtuzumab treatment of a relapsing-remitting multiple sclerosis (RRMS) patient.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Outpatient neurology research protocol.
  
  
  METHODS
  A 35-year-old white female receiving alemtuzumab for RRMS in a clinical research protocol developed symptoms leading to diagnosis of anti-GBM disease.
  
  
  METHODS
  Patient response to the treatment of anti-GBM disease and RRMS.
  
  
  RESULTS
  Early identification and treatment of anti-GBM disease resolved clinical symptoms and preserved renal function. Alemtuzumab treatment of RRMS resolved initial MS symptoms and appears to have controlled active disease to date.
  
  
  CONCLUSIONS
  Close monitoring for potential side effects of alemtuzumab treatment in RRMS resulted in a positive outcome when anti-GBM disease was recognized and treated early.
authors: Triad Neurological Associates, Cornerstone Health Care, 145 Kimel Park Drive, Suite 100, Winston Salem, NC 27103, USA. Electronic address: David.Meyer@cornerstonehealthcare.com.
authors: David
authors: D
authors: Meyer
authors: Department of Neurosciences, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. Electronic address: ajc1020@medschl.cam.ac.uk.
authors: Alasdair
authors: A
authors: Coles
authors: Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: pedro.oyuela@genzyme.com.
authors: Pedro
authors: P
authors: Oyuela
authors: Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: annie.purvis@genzyme.com.
authors: Annie
authors: A
authors: Purvis
authors: Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: david.margolin@genzyme.com.
authors: David H
authors: DH
authors: Margolin
keywords: Alemtuzumab; Anti-glomerular basement membrane disease; Autoimmune disease; Goodpasture's syndrome; Multiple sclerosis; Pulmonary renal syndrome